Carna Acquires Market Rights to CrystalGenomics Kinase Crystallization Offerings | GenomeWeb

NEW YORK, Feb. 21 (GenomeWeb News) - Carna Biosciences has acquired the exclusive worldwide rights to sell CrystalGenomics' kinase crystallization-related products and services, the companies said today.

Specific terms of the deal were not disclosed.

Carna, which is based in Japan, and CrystalGenomics, which is based on Korea, have been jointly researching kinase inhibitors since forming an alliance in June 2004.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.